Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Apr 27:21:200272.
doi: 10.1016/j.ijcrp.2024.200272. eCollection 2024 Jun.

Treatment of obesity with liraglutide in cardiovascular prevention: Case series by the "ITACARE-P Light-Heart Lab" working group

Francesco Maranta  1 , Francesca Buffoli  2 , Vittorio Giudici  3 , Gabriella Malfatto  4 , Alessandro Maloberti  5   6 , Luigi Maresca  7 , Bruno Passaretti  8 , Anna Torri  9 , Roberto Turato  10 , Marco Ambrosetti  11
Affiliations
Review

Treatment of obesity with liraglutide in cardiovascular prevention: Case series by the "ITACARE-P Light-Heart Lab" working group

Francesco Maranta et al. Int J Cardiol Cardiovasc Risk Prev. .
No abstract available

Keywords: Cardiac rehabilitation; Cardiovascular prevention; Obesity.

PubMed Disclaimer

Conflict of interest statement

The authors declare they have no conflict of interest.

References

    1. Maranta F., Cianfanelli L., Regoni M., Cianflone D. Cardiologist and diabetologist crosstalk in the era of cardiovascular outcome trials of novel glucose-lowering drugs. IJC Heart Vasc. 2018;21:80–86. - PMC - PubMed
    1. Lincoff A.M., Brown-Frandsen K., Colhoun H.M., Deanfield J., Emerson S.S., Esbjerg S., et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N. Engl. J. Med. 2023;389(24):2221–2232. - PubMed
    1. Nikolic D., Giglio R.V., Rizvi A.A., Patti A.M., Montalto G., Maranta F., Cianflone D., Stoian A.P., Rizzo M. Liraglutide reduces carotid intima-media thickness by reducing small dense low-density lipoproteins in a real-world setting of patients with Type 2 diabetes: a novel anti-atherogenic effect. Diabetes Ther. 2021;12(1):261–274. - PMC - PubMed
    1. Pi-Sunyer X., et al. A Randomized, controlled trial of 3.0 mg of liraglutide in weight management. N. Engl. J. Med. 2015;373:11–22. - PubMed
    1. Visseren F.L.J., Mach F., et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: developed by the task force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies with the special contribution of the European Association of Preventive Cardiology (EAPC) Eur. Heart J. 2021;42:3227–3337. - PubMed

LinkOut - more resources